AKILI, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4272 USD | -3.87% |
|
+6.37% | -12.30% |
| 04-30 | Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product | CI |
| 04-30 | Akili, Inc. to Reduce Workforce | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 316.7 | 87.26 | 38.14 | 33.58 | - | - |
| Enterprise Value (EV) 1 | 316.7 | 49.51 | -24.31 | -32.82 | -54.42 | 33.58 |
| P/E ratio | -0.09 x | -1.75 x | -0.64 x | - | - | - |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 270 x | 22.7 x | 4.39 x | 2.88 x | 3.93 x |
| EV / Revenue | - | 153 x | -14.5 x | -4.29 x | -4.66 x | 3.93 x |
| EV / EBITDA | - | -0.63 x | 0.38 x | 0.86 x | 1.91 x | -1.05 x |
| EV / FCF | - | -592,449 x | - | - | - | - |
| FCF Yield | - | -0% | - | - | - | - |
| Price to Book | - | 0.3 x | 0.65 x | 0.79 x | 0.69 x | - |
| Nbr of stocks (in thousands) | 31,890 | 77,909 | 78,310 | 78,596 | - | - |
| Reference price 2 | 9.930 | 1.120 | 0.4871 | 0.4272 | 0.4272 | 0.4272 |
| Announcement Date | 04/04/22 | 07/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.323 | 1.678 | 7.643 | 11.67 | 8.548 |
| EBITDA 1 | - | -78.01 | -64.18 | -38.02 | -28.54 | -32.03 |
| EBIT 1 | - | -78.32 | -64.48 | -38.34 | -28.88 | -32.37 |
| Operating Margin | - | -24,248.3% | -3,842.97% | -501.68% | -247.46% | -378.65% |
| Earnings before Tax (EBT) | - | -7.945 | -59.44 | - | - | - |
| Net income | -126.7 | -7.964 | -59.49 | - | - | - |
| Net margin | - | -2,465.63% | -3,545.47% | - | - | - |
| EPS | -105.8 | -0.6400 | -0.7600 | - | - | - |
| Free Cash Flow | - | -83.56 | - | - | - | - |
| FCF margin | - | -25,870.9% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 04/04/22 | 07/03/23 | 29/02/24 | - | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.082 | 0.111 | 0.113 | 0.114 | 0.702 | 0.749 | 0.794 | 0.873 | 0.951 | 1.03 | 1.188 |
| EBITDA 1 | -18.23 | -19.91 | -12.02 | - | -18.35 | -11.55 | -10.03 | -9.323 | -9.276 | -8.642 | -8.543 |
| EBIT 1 | -18.31 | -19.99 | -19.12 | -15.32 | -18.43 | -11.62 | -10.1 | -9.4 | -9.353 | -8.718 | -8.623 |
| Operating Margin | -22,325.61% | -18,009.01% | -16,919.47% | -13,435.96% | -2,624.79% | -1,551.8% | -1,272.67% | -1,076.75% | -983.49% | -846.41% | -725.84% |
| Earnings before Tax (EBT) | 53.24 | - | - | - | -15.88 | -11.09 | - | - | - | - | - |
| Net income 1 | 53.24 | -16.82 | -20.71 | -11.76 | -15.88 | -11.15 | -11.19 | -10.48 | -10.43 | -9.799 | -9.76 |
| Net margin | 64,921.95% | -15,148.65% | -18,328.32% | -10,314.91% | -2,261.54% | -1,488.25% | -1,408.82% | -1,200.46% | -1,097.06% | -951.36% | -821.55% |
| EPS 2 | 0.7600 | -0.4800 | -0.2700 | -0.1500 | -0.2000 | -0.1400 | -0.1400 | -0.1300 | -0.1300 | -0.1200 | -0.1200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/11/22 | 07/03/23 | 12/05/23 | 10/08/23 | 09/11/23 | 29/02/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 37.8 | 62.5 | 66.4 | 88 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -83.6 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | -60.2% | -74.2% | -35.8% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 3.700 | 0.7500 | 0.5400 | 0.6200 | - |
| Cash Flow per Share | - | -2.800 | - | - | - | - |
| Capex | - | 0.04 | - | - | - | - |
| Capex / Sales | - | 13% | - | - | - | - |
| Announcement Date | 04/04/22 | 07/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4272
USD
Average target price
0.65
USD
Spread / Average Target
+52.15%
| 1st Jan change | Capi. | |
|---|---|---|
| -12.30% | 33.58M | |
| +11.73% | 226B | |
| +9.53% | 188B | |
| +14.63% | 137B | |
| +27.47% | 108B | |
| -0.04% | 63.19B | |
| +13.73% | 52.26B | |
| +4.86% | 51B | |
| +7.72% | 43.89B | |
| +7.86% | 38.07B |
- Stock Market
- Equities
- AKLI Stock
- Financials Akili, Inc.
